Company: SXTPW
Filing Date: 2025-06-06
Form Type: DRS
Source: 0001213900-25-052232
Chunk: 30

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-06-06
Form: DRS
Chunk 30
---
 twelve months (the “Option Period”), unless terminated earlier upon execution of a license agreement
or pursuant to the termination provisions in the Option Agreement. During the Option Period, the Company may use Patent and Technology
Rights solely for evaluation purposes.

The Option Agreement also includes certain provisions
relating to indemnification and termination rights. The Option Agreement and the Option Rights shall not be assignable, whether by operation
of law or otherwise, and any attempt to do so shall be void.

Castanospermine is a bioactive alkaloid derived
from the Australian Chestnut tree (Castanospermum australe). The Company has a long-standing intellectual property position around
the development of a synthetic castanospermine derivative, celgosivir, for viral diseases. Moreover, extensive scientific literature suggests
short-course botanically-derived castanospermine regimens may potentially beneficial metabolic and immunomodulatory effects. The development
and commercialization route for botanical extracts is far more efficient and less costly than for prescription pharmaceuticals.

<div align='center'>11</div>

Registered Direct Offerings

February 2025 Offering

On February 5, 2025, we entered into a securities
purchase agreement (the “February 2025 Securities Purchase Agreement”) with certain institutional investors (the “February
2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 300,700 shares (the “February
2025 Shares”) of common stock at a purchase price of $3.575 per share in a registered direct offering (the “February 2025
Offering”) priced at-the-market under the rules of The Nasdaq Stock Market LLC (“Nasdaq”). The February 2025 Offering
closed on February 6, 2025.

The February 2025 Shares were offered pursuant
to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on
July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025 and accompanying
base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

In a concurrent private placement, the Company
also issued to the February 2025 Purchasers unregistered warrants (the “February 2025 Warrants”) to purchase up to an aggregate
of 300,700 shares of common stock